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IMPORTANCE US guidelines recommend that physicians engage in shared decision-making
with men considering prostate cancer screening.
OBJECTIVE To estimate the association of decision aids with decisional outcomes in prostate
cancer screening.
DATA SOURCES MEDLINE, Embase, PsycINFO, CINAHL, and Cochrane CENTRALwere
searched from inception through June 19, 2018.
STUDY SELECTION Randomized trials comparing decision aids for prostate cancer screening
with usual care.
DATA EXTRACTION AND SYNTHESIS Independent duplicate assessment of eligibility and risk
of bias, rating of quality of the decision aids, random-effects meta-analysis, and Grading
of Recommendations, Assessment, Development and Evaluations rating of the quality
of evidence.
MAIN OUTCOMES ANDMEASURES Knowledge, decisional conflict, screening discussion,
and screening choice.
RESULTS Of 19 eligible trials (12 781 men), 9 adequately concealed allocation and 8 blinded
outcome assessment. Of 12 decision aids with available information, only 4 reported the
likelihood of a true-negative test result, and 3 presented the likelihood of false-negative test
results or the next step if the screening test result was negative. Decision aids are possibly
associated with improvement in knowledge (risk ratio, 1.38; 95% CI, 1.09-1.73; I2 = 67%;
risk difference, 12.1; low quality), are probably associated with a small decrease in decisional
conflict (mean difference on a 100-point scale, −4.19; 95% CI, −7.06 to −1.33; I2 = 75%;
moderate quality), and are possibly not associated with whether physicians and patients
discuss prostate cancer screening (risk ratio, 1.12; 95% CI, 0.90-1.39; I2 = 60%; low quality)
or with men’s decision to undergo prostate cancer screening (risk ratio, 0.95; 95% CI,
0.88-1.03; I2 = 36%; low quality).
CONCLUSIONS AND RELEVANCE The results of this study providemoderate-quality evidence
that decision aids compared with usual care are associated with a small decrease in decisional
conflict and low-quality evidence that they are associated with an increase in knowledge but
not with whether physicians and patients discussed prostate cancer screening or with
screening choice. Results suggest that further progress in facilitating effective shared
decision-makingmay require decision aids that not only provide education to patients but are
specifically targeted to promote shared decision-making in the patient-physician encounter.
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O wing to increasing use of prostate-specific antigen(PSA) screening, the incidence of early-stage pros-tate cancerhas increasedduring the last 25years.1Ad-
vocatesofscreeningoftencite theEuropeanRandomizedstudy
of Screening for Prostate Cancer (ERSPC)2—of the available
trials, the one at lowest risk of bias3—that suggested that PSA
screening reduces prostate cancer–specific mortality but not
overall mortality.2 Opponents of screening often cite an ear-
lier meta-analysis4 or other major trials5,6 that reported no
association between PSA screening and prostate cancer–
specificmortalityandpointoutpossibleharmsassociatedwith
surgery or radiotherapy.7
Men’s choice of whether to undergo prostate cancer
screening is sensitive to their values and preferences: that is,
fully informed men will make different choices depending
on their experience and perspective. For such decisions,
shared decision-making, characterized by cooperative com-
munication between patient and clinician in which they
share knowledge, values, and preferences, represents an
ideal approach to decision-making.8 Major guidelines
therefore acknowledge the importance of informing men
about the risks and benefits of PSA screening.9-12 The US
Preventive Services Task Force has recently recommended
that the decision to undergo prostate cancer screening
should be an individual one in which men should discuss
potential benefits and harms with their clinician before
screening and recommended that men who do not express a
clear preference for screening should not be screened.11
Even more recently, a BMJ Rapid Recommendations’
panel made a weak recommendation against systematic
PSA screening that acknowledged the need for shared
decision-making.12
Shared decision-making is challenging because of time
constraints and the specific skills that it requires.13 Well-
designed decision aids may, at least in part, address these
challenges by summarizing the current best evidence and by
supporting conversations that address the issues that matter
most to patients.14,15 The association of decision aids with
the decision-making process remains, however, uncertain.8
We therefore undertook a systematic review and meta-
analysis of the randomized clinical trials (RCTs)—many of
which were conducted before major PSA trials,2,5,6 such as
ERSPC,2 were published—that have addressed the effect of
decision aids on the decision-making process in the context
of prostate cancer screening.
Methods
We registered the protocol in the International Prospective
RegisterofSystematicReviews (PROSPEROCRD42016052816)
and followed the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) reporting guideline.16
Data Sources and Searches
Weperformed the search, developed in collaborationwith an
experienced research librarian (R.C.), on June 19, 2018, in
MEDLINE, Embase, CINAHL, PsychINFO, and Cochrane
Central Register of Controlled Trials (CENTRAL) without
language limits (eAppendix 1 in the Supplement).
Eligibility Criteria
We included RCTs conducted among men who were poten-
tially considering undergoing prostate cancer screening that
compareddecisionaid interventions forprostatecancerscreen-
ingwithusual care.Weevaluateddecisionaids and studypro-
tocols and judged interventions as either decision aids, infor-
mationmaterial, orusual care (notoverlappingcategories).We
definedthe interventionsasdecisionaids if thematerialhelped
menmaking individual choices and included information re-
garding theassociationof screeningwith the followingpatient-
important outcomes: risk of dying, risk of urinary or bowel
symptoms, and riskof erectiledysfunction.Wedefined the in-
terventionasusual care if cliniciansprovidedno formal, struc-
tured presentation of information and informativematerial if
interventions provided some structured information but did
not meet our definition of a decision aid (eAppendix 2 in the
Supplement).
Weexcluded studies comparing onedecision aidwith an-
other and those thatdidnot report onanyofour specifiedout-
comes (see theOutcomes subsection).Wealso excluded stud-
ies in which less than 50% of participants in intervention
groups used a decision aid.
Outcomes
We evaluated the following outcomes: knowledge regarding
prostate cancer screening, decisional conflict, discussions re-
garding screening betweenmenand their physicians (screen-
ingdiscussion),decisionsdeterminingwhether screening took
place (actual screeningdecision), andsatisfactionwith screen-
ing decision.
Risk of Bias and the Quality of Decision Aids
We assessed the risk of bias using a modified version of the
Cochrane Collaboration risk of bias tool addressing 5 criteria
(eAppendix 3 in the Supplement). For each criterion, studies
were judged tobeat eitherhighor lowriskofbias. Studieswith
Key Points
Question What is the association of decision aids vs usual care
with shared decision-making in men deciding whether to undergo
prostate cancer screening?
Findings This systematic review andmeta-analysis of 19
randomized clinical trials comparing decision aids for prostate
cancer screening (12 781 men) found that decision aids are
probably associated with a small reduction in decisional conflict
and are possibly associated with an increase in knowledge.
Decision aids are possibly not associated with whether physicians
and patients discuss prostate cancer screening and are possibly
not associated with actual screening decisions.
Meaning Randomized clinical trials have failed to provide
compelling evidence for the use of decision aids for men
contemplating prostate cancer screening that have, up to now,
undergone rigorous testing to determine their outcome.
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ahigh risk of bias for 3 ormore criteriawere classified as being
at high risk of bias overall.
We identified decision aids used in the studies by follow-
ing a multistep approach: (1) we first reviewed original ar-
ticles to identify links or references to electronically available
decision aids or those provided as appendices; (2) if unavail-
able, we conducted electronic searches for decision aids on-
line; and (3) we contacted study authors by email, requesting
access to the decision aid. We evaluated the available deci-
sion aids using a modified version of the International Pa-
tientDecisionAidStandards instrument (IPDASi), version3 for
screening17 byassessing 10criteria (eAppendix4 in theSupple-
ment). We rated each criterion asmet or unmet and summed
the number of criteria met.
Study Selection and Data Extraction
We developed standardized forms with detailed instructions
for screening of abstracts and full texts, risk of bias, quality of
assessments of decision aids, and data extraction. Indepen-
dently and in duplicate, 2 methodologically trained review-
ers (J.M.R., T.P.K., S.C., A.A., P.J., N.P., P.O.R., J.R., H.S., and
T.T.) applied the forms to screen study reports for eligibility
andextracteddata.Reviewers resolveddisagreement through
discussion and, if necessary, through consultation with an
adjudicator (K.A.O.T.). We sent our consensus data extrac-
tion to the original authors for confirmation or correction
and asked for clarification regarding missing or unclear
information.
Statistical Analysis
For continuous outcomes in which investigators used differ-
ent instruments tomeasureaconstruct,westandardizedscores
onarange from0to10018,19 andsummarizedthedataasmeans
and SDs or, for skewed distributions, medians and interquar-
tile ranges. For continuous variables, we expressed effects as
meandifferencesand95%CIsand forbinaryoutcomes, as rela-
tive risks and 95% CIs. To obtain the absolute difference, we
chose the percentage correct of the median of the control
groups and applied the point estimate and 95% CIs of the
pooled relative risk to that value.We categorized outcome ef-
fects as short-term (effect estimated ≤1 month after decision
aid use) and long-term (>1 month after decision aid use) and
focused on the last time point in either period in the primary
analysis. AllPvalueswere from2-sided tests, and resultswere
deemed statistically significant at P < .05.
We conducted meta-analyses when data for a particular
outcomewere available from at least 3 trials. For studieswith
more than 1 intervention group, if we failed to reject the null
hypothesis that the intervention groups did not differ (z test
at 5% significance level), we pooled the groups within the
study; if results differed,weusedonly thegroupwith the larg-
est effect. To study the potential differences in intervention
effects on the outcomes by length of follow-up (short-term
defined as ≤1month and long-termas >1month),we first con-
ductedtherepeatedmeasure, random-effects,weightedmixed
regressionmodelanalysis.Thedependentvariablewas theout-
comemeanand the independent variableswere the interven-
tion, the follow-up term, the interaction of intervention and
follow-up term, the randomeffects in study, and the baseline
data.We reported the pooled analyses separately by length of
follow-up if the interaction effect was significant; if not, we
reported analyses using the longest follow-up. For analyses in
which the I2 statistic was greater than 0%, we pooled the re-
sults using Hartung-Knapp-Sidik-Jonkman random-effects
models. If the I2 statisticwas0%,wepooled resultsusing fixed-
effects models because, under these circumstances, the
fixed-effectsmethod is superior to theHartung-Knapp-Sidik-
Jonkman method in type I error.20 We examined the follow-
ingvariables aspotential sourcesofheterogeneityusingmeta-
regression: allocationconcealment, blindingofdata collectors,
and missing data (low vs high risk of bias for all variables).
We hypothesized that effects would be larger in high-risk-of-
bias trials.
Quality of Evidence
To assess the quality of evidence, we used the Grading of
Recommendations, Assessment, Development and Evalua-
tions (GRADE) approach that classifies evidence ashigh,mod-
erate, low, or very low quality.21 We used published GRADE
guidancefor ratingsof riskofbias,22consistency,23directness,24
precision,25 and publication bias.26 Wemade 1 major modifi-
cation of GRADE: the GRADE quality of evidence ratings are
intended to address causal inferences; because of journal
policy, we applied the quality ratings to issues of association.
Results
Of 12032 potentially relevant reports, 238 proved potentially
eligible; after full-text screening, 19 articles27-45 proved eli-
gible (Figure 1). Six of the 19 authors (32%) confirmed the ac-
curacyof our data extraction28,33,37,39,42,43; none corrected er-
rors or addedadditional information. Elevenof the 19 authors
(58%)27,29,30,32,34,35,38,40,41,44,45 could not be contacted, and 2
authors (11%)31,36were unable to assist. Trialswere published
between 1999and2017 (eFigure 1 in theSupplement) and ran-
domized 12 781 men; the median of mean ages was 59 years
(interquartile range, 57-62 years). Sixteen studies were per-
formed in the United States, 2 in the United Kingdom, and 1
in Canada (Table 1).
Risk of Bias
In all 19 studies, the allocation sequence was adequately
generated; in 9 studies (47%), allocationwas adequately con-
cealed; and in 8 studies (42%), data collectors were blinded.
Missing data were judged as high risk of bias in 7 of 13 studies
(54%) for actual screening decision and in 11 of 19 studies
(58%) for other outcomes (knowledge, screening discussion,
decisional conflict, and satisfaction with decision) (Table 1;
eFigure 2 in the Supplement).
Decision Aids
Investigators used several types of decision aids: 13 of 19
studies used printed material (8 used booklets of 8-28
pages29,30,34,35,38-40,42and5usedleafletsof1-2pages27,28,41,43,45),
5 studiesusededucation (2usedgroupsessions33,37 and3used
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individual education30,31,44), 5 studies used computer-based
tools,29,32,34,36,39 and 4 studies used videos.31,40,42,45 Two
studies used the same video.42,45 One study used shared
decision-making27 (eTable 1 in the Supplement).
We identified 12 decision aids: 5 by reviewing original
articles,28,30,31,41,434byelectronicsearches,29,34,38,40and3from
theauthors.39,42,45 Twoauthors reported that thedecision aid
wasno longeravailable (eTable 1 in theSupplement).35,44Three
decision aids scoredwell (8-10 points out of 10), 4 scored less
well (5-7 points), and 5 scored poorly (≤4 points); the overall
IPDASi mean (SD) score was 5.6 (2.9) (range, 2-10). All deci-
sionaids reportedthescreeningaim;11of 12decisionaids (92%)
reported the association of screeningwith overall or prostate
cancer–specificmortality; and 10 of 12 decision aids (83%) re-
ported the harms of the increase in surgery and radiotherapy
that accompanies the increased diagnosis of prostate cancer
consequent to screening (erectile dysfunction, urinary incon-
tinence, and bowel problems). Four of 12 decision aids (33%)
presented information regarding the probability of having a
true-negative result; 3 of 12 decision aids (25%) presented the
probability of a false-negative result or thenext step if screen-
ing results were negative. Two of 12 decision aids (17%)
presented the likelihoodofdetectingprostate cancerwith and
without the use of screening (eFigure 3 in the Supplement).
Outcomes
Knowledge
Of the 13 studies reporting short-term knowledge, 8 reported
data as a continuous variable and 5 reported the proportion
of correct items.Because theSDsof the latter aremuchsmaller
(owing to the nature of binomial distribution), they would
dominate a pooled result of all 13 studies; therefore, we ana-
lyzed them separately. Pooled estimates from 8 studies re-
porting data as a continuous variable showed an increase in
knowledge for decision aids (mean difference, 16.29; 95%CI,
3.45-28.94; low-quality evidence;Table 2 andFigure 2B). The
proportion of correctness data from 5 studies demonstrated
improvedknowledgewithdecision aids, although the95%CI
includes a very small and likely unimportant difference (risk
ratio, 1.38; 95%CI, 1.09-1.73; risk difference, 12.1; low-quality
evidence; Table 2 and Figure 2A). Studies failed to demon-
strate an association with knowledge in the long term (mean
difference, 5.47; 95% CI, −0.52 to 11.45; low-quality evi-
dence; eFigure 4 in the Supplement).
Decisional Conflict
In the pooled analysis (6 studies), the decision aids were as-
sociated with a small but consistent and statistically signifi-
cantdecrease indecisional conflict (meandifferenceona 100-
point scale, −4.19; 95% CI, −7.06 to −1.33; moderate-quality
evidence; Table 2 and Figure 3A).
Screening Discussion
The frequencywithwhich a screeningdiscussionwith the cli-
nician tookplacevaried from8%to97%(median,47%) inusual
care groups and from 16% to 99% in decision aid groups (me-
dian, 52%). The pooled analysis from6 studies failed to dem-
onstrate an associationwithwhether physicians andpatients
discussed prostate cancer screening (risk ratio, 1.12; 95% CI,
0.90-1.39; low-quality evidence; Table 2 and Figure 3B). In 4
studies,28,39,42,43 thedecision aidwasdistributed 1 to 2weeks
before thevisit or assessment; in 1 study,31 thedecisionaidwas
distributed 1 hour before the assessment; and in 1 study,30 the
decision aid was distributed 8 months before the visit.
Actual Screening Decision
The frequency with which men choose to undergo prostate
cancer screening ranged from 5% to 94% (median, 49%) in
usual care groups and 5% to 90% in decision aid groups (me-
dian, 49%). The pooled analysis from 13 studies demon-
stratedno association inmen’s decision toundergo or not un-
dergoprostate cancer screeningbetween thedecision aid and
usual care groups (risk ratio, 0.95; 95% CI, 0.88-1.03; low-
quality evidence; Table 2 and Figure 3C).
SatisfactionWith Decision
Three studies29,40,45 reportedmen’s satisfactionwith their de-
cision; 2 of these studies used the Satisfaction with Decision
Scale,29,45,46 and 140 used a Likert scale. Two studies re-
ported no difference in satisfaction between the intervention
andcontrol groups.40,46Onestudy29 reported thatmen inboth
thegroup that receivedaprinteddecisionaid (odds ratio [OR],
1.79; 95% CI, 1.41-2.29) and the group that received a web-
baseddecisionaid (OR, 1.29;95%CI, 1.02-1.66)weremore likely
to report high satisfaction at 1 month of follow-up compared
with usual care (high satisfaction reported by 60.4% in the
printed decision aid group and 52.2% in the web decision aid
group comparedwith45.5% in the control group). This differ-
ence persisted compared with the usual care group for the
printeddecisionaidgroup (OR, 1.29; 95%CI, 1.01-1.66) butnot
for theweb-based decision aid group (OR, 1.04; 95%CI, 0.81-
1.34) at 13monthsof follow-up.Furthermore,participantswith
printedmaterial reportedsignificantlygreater satisfaction than
withwebmaterial at 1month (OR, 1.38; 95%CI, 1.07-1.77) but
not at 13 months (OR, 1.24; 95% CI, 0.96-1.60). None of these
studies examinedwhether satisfaction varied bywhether the
Figure 1. Flowchart Outlining the Literature Search
and Article Evaluation Process
12 032 Reports from keyword and index term searches in
MEDLINE, Embase, PsychINFO, CENTRAL, and CINAHL
238 Retrieved for full text evaluation
19 Fulfilled eligibility criteria
11 794 Excluded after title and abstract
review
219 Excluded due to failure to satisfy
inclusion criteria
32 Not evaluating decision aids on
prostate cancer screening
148 Not a randomized trial
26 No usual care control group
7 Intervention was not decision aid
1 Low decision aid adherence
5 No relevant outcomes
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decision was to undergo prostate cancer screening or not to
undergo screening. Fornooutcomedid riskof bias explain the
variability in results (eTable 2 in the Supplement).
Discussion
Main Findings
To examine the association of prostate cancer screening de-
cision aids with decisional outcomes and screening deci-
sions,wepooleddata from19 trials. Low-qualityevidence sug-
gests that decision aids are associated with an improvement
inmen’s knowledge regarding prostate cancer screening, and
moderate-quality evidence suggests that decision aids are as-
sociated with a small decrease in decisional conflict. Overall,
decision aids proved to not be statistically significantly asso-
ciated with whether physicians and patients discussed pros-
tate cancer screening, orwithmen’sdecision toundergoornot
undergo screening (low-quality evidence). The decision aids
used in these studies provided most of the crucial informa-
tion (benefits and harms of screening) but typically omitted
test properties of the screening tests.
Strengths and Limitations of the Study
Strengths of our study include a comprehensive search, du-
plicate assessment of eligibility and data extraction, ap-
praisal of risk of bias, use of outcomes that are important to
patients, and evaluation of decision aids using the IPDASi in-
strument. To increase the precision of estimates, whenever
possible, we conductedmeta-analyses using appropriate sta-
tistical methods. The GRADE approach was applied to assess
the quality of evidence for each outcome (Table 2).
Limitations of our review are largely those of the avail-
able literature. First, wewere not able to use all studies: in 26
Table 2. GRADE Evidence Profile: Decision Aid vs Usual Care for Prostate Cancer Screening
Quality Assessment Summary of Findings
No. of Patients
With Data
(No. of Studies) Risk of Bias Inconsistency Indirectness Imprecision Publication Bias
Relative Effect
(95% CI)
Absolute
Difference
(95% CI)
Certainty
in Estimates
Knowledge (short-term; percentage correct)
1167 (5) Serious
limitationsa
No serious
limitations
No serious
limitations
Serious limitations:
CI includes a very
small and likely
unimportant
difference
Undetected Decision aid
increased
discussion about
prostate cancer
screening by 38%
(from 9% to 73%
increase)
Mean difference
of 12.1 (from 2.9
increase to 24.5
increase) on
percentage correct
favoring decision
aid
Lowb
Knowledge (short-term; continuous)
4272 (8) Serious
limitationsc
No serious
limitations
No serious
limitations
Serious limitations:
CI includes a very
small and likely
unimportant
difference
Undetected NA Mean difference
of 16.3 (from 3.5
increase to 28.9
increase) on
100-point scale
favoring decision
aid
Lowb
Decisional Conflict
3700 (6) Serious
limitationsd
No serious
limitations
No serious
limitations
No serious
limitations
Undetected NA Mean difference
of 4.2 (from 1.3
to 7.1) on
100-point scale
favoring decision
aid
Moderatee
Screening Discussion
1927 (6) Serious
limitationsf
No serious
limitations
No serious
limitations
Serious limitations:
CI crosses no
difference
Undetected Decision aid
increased
screening
discussion by
12% (from 10%
decrease to 39%
increase)
No significant
effect
Lowb
Actual Screening Decision
4286 (13) Serious
limitationsg
No serious
limitations
No serious
limitations
Serious limitations:
CI crosses no
difference
Undetected Decision aid
decreased
screening by 5%
(from 13%
decrease to 4%
increase)
No significant
effect
Lowb
Abbreviations: GRADE, Grading of Recommendations, Assessment,
Development and Evaluations; NA, not applicable.
a Of the 5 studies, 3 (60%) were at high risk of bias, and 2 (40%) were at low
risk of bias (Table 1; eFigure 2 in the Supplement).
b The low quality of the rating reflects concerns in 3 domains: risk of bias,
inconsistency, and imprecision.
c Of the 8 studies, 6 (75%) were at high risk of bias, and 2 (25%) were at low risk
of bias (Table 1; eFigure 2 in the Supplement).
dOf the 6 studies, 5 (83%) were at high risk of bias, and 1 (17%) was at low risk
of bias (Table 1; eFigure 2 in the Supplement).
e Themoderate quality of rating reflects concerns in 2 domains: risk of bias and
imprecision.
f Of the 6 studies, 4 (67%) were at high risk of bias, and 2 (33%) were at low risk
of bias (Table 1; eFigure 2 in the Supplement).
g Of the 13 studies, 11 (85%) were at high risk of bias, and 2 (15%) were at low
risk of bias (Table 1; eFigure 2 in the Supplement).
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studies, there was no usual care control group, 5 studies did
not report on any of our outcomes, and 1 study had very low
adherence to thedecisionaid (eTable3 in theSupplement).Sec-
ond, we were able to conduct IPDASi evaluation in only 12
decision aids used in 13 studies. Third, most trials were per-
formed before major PSA trials—ERSPC2; Prostate, Lung, Co-
lorectal, andOvarianCancerScreeningTrial5; andClusterRan-
domized Trial of PSA Testing for Prostate Cancer6—provided
data (eFigure 1 in the Supplement). Fourth, different instru-
mentswereused forassessmentofknowledge.Fifth,we found
only low-quality evidence for the association of decision aids
with knowledge, whether a screening discussion was con-
ducted, or patients’ decisions whether to undergo screening.
Furthermore, many available decision aids have not under-
gone formal testing in randomized trials.
AssociationWith Other Studies
Three previous systematic reviews have investigated deci-
sion aids for prostate cancer screening.47-49 One review pub-
lished more than 10 years ago addressed different questions
and did not include 14 studies included in our review.47
A systematic reviewpublished in 2015 concluded that de-
cision aids increase patient knowledge and confidence in
decision-making regarding prostate cancer testing.48 This re-
view included 13 studies, of which we did not include 6
studies50-55becauseof the lackofastandardcarecontrolgroup,
but it failed to include 12 trials that proved to be eligible in our
systematic review: 11 RCTs of decision aids that were re-
ported before the publication of their review and apparently
met their eligibilitycriteria28,35-41,43-45 andonestudy27 thatwas
published after their review appeared. The authors failed to
conduct a meta-analysis.48
Ivlevandcolleagues49havepublished themost recent sys-
tematic review on prostate cancer screening patient decision
aids and concluded that integration of decision aids in clini-
cal practicemay result in adecrease in thenumberofmenwho
elect toundergoPSA testing,whichmay in turn reduce screen-
ing uptake. Support for this statement came from an analysis
of intent to screen (risk ratio, 0.88; 95% CI, 0.81-0.95). Their
meta-analysis of 2 RCTs that addressedmen’s actual decision
found, however, no difference between the decision aid and
usual caregroups (risk ratio,0.92;95%CI,0.62-1.36)and iscon-
sistent with our analysis of 13 RCTs (risk ratio, 0.95; 95% CI,
0.88-1.03).
The review by Ivlev et al49 included 13 RCTs and 5 obser-
vational studies; to avoid bias associatedwith prognostic im-
balance,we restrictedour eligible studies toRCTs.Of theRCTs
that Ivlev and colleagues49 included, we did not include 3
studies54-56 because they did not have a standard care con-
trol groupand 1 study57 because it lackedourprespecifiedout-
comes. The review by Ivlev et al49 failed to include 10 of our
19eligible trials: 3 trials28,31,33wereconsidered—contrary toour
judgment—as not having a decision aid group, 3 trials29,35,38
were excluded because they did not meet their eligibility
criteria of reporting immediate or deferred intention or utili-
zation data, 1 trial44 was excluded without explanation, and
Figure 2. Forest Plots of Short-term Prostate Cancer Screening Knowledge
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3 trials37,40,43were eithernot identifiedby their searchorwere
excluded during title and abstract screening (not possible to
distinguishwhichreason).Otherdifferences includedourmea-
suring of screening discussions and reporting a meta-
analysis of decisional conflict, which were not in the review
by Ivlev et al.49 Ivlev and colleagues49 stated in their meth-
ods (including PROSPERO CRD42017060606) that they used
theGRADEapproach21;however, theyprovidedevidencequal-
ity for only 2 outcomes: intention to undergo PSA testing and
knowledge. Our judgments applying the GRADE approach21
included all outcomes and differed from the review by Ivlev
et al49 regarding knowledge because we considered the fail-
ure to use blinded assessments as a reason to rate the quality
of evidence downward and they did not.
Implications for Clinicians and Policymakers,
and Future Directions
Our results suggest modest and uncertain associations be-
tween existing decision aids and key outcomes: a possible in-
crease in knowledge and likely a small decrease in decisional
Figure 3. Forest Plots of Prostate Cancer Screening Decisional Conflict,
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conflict but no apparent associationwithwhether physicians
andpatientsdiscussedprostate cancer screeningorwithmen’s
decision to undergo or not undergo prostate cancer screen-
ing. Many prostate cancer screening decision aids are avail-
able online, but only a fewhaveundergone formal testing. All
decisions aids included in our review provided education to
patients, and all but 1 decision aid27 failed to showclear facili-
tationof screeningdiscussions (ie, shareddecision-making).14
The resultsdemonstrate a lackofprostate cancerdecisionaids
specifically geared toward or successful in facilitating shared
decision-making.
The best available evidence suggests that PSA screening
mayhavea small, althoughuncertain, benefit onprostate can-
cer mortality.3 Evidence shows, however, that PSA screening
alsoharmsmenbecauseof false-positive test results andover-
diagnosisandovertreatmentofprostatecancer.3Before thema-
jor prostate cancer screening trials reported their results,2,5,6
there was insufficient evidence to recommend for or against
screening. In our meta-analysis, only 2 trials27,28 began re-
cruitment of patients after ERSPC and the Prostate, Lung, Co-
lorectal, andOvarianCancerScreeningTrialhadpublishedtheir
results (eFigure 1 in the Supplement). Although these 2
trials27,28 reported results similar toourpooledresults, it ispos-
sible that decision aids with new, updated evidence summa-
riesmayhavemore benefit than earlier decision aids inwhich
results weremore uncertain. There is therefore a call for new
trialswithupdateddecisionaids.12 In general, trustworthyde-
cision aids require links to recent evidence-based summaries
and clinical practice guidelines that carry out dynamic
updating.12,14
Conclusions
Randomized clinical trials provide moderate-quality evi-
dence that decision aids are associated with a small reduc-
tion in decisional conflict, while low-quality evidence sug-
gests that they are associated with an increase in knowledge
but not with whether physicians and patients discuss pros-
tate cancer screeningorwithmen’s decision toundergoornot
undergoprostatecancerscreening.Theavailableevidencedoes
not provide a compelling rationale for clinicians to use exist-
ing decision aids to facilitate shared decision-making in their
discussions with men considering undergoing prostate can-
cer screening. Future decision aids should include provision
for continuous updating and not only provide education to
patients but also promote shared decision-making in the
patient-physician encounter.
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Invited Commentary
Decision Aids for Prostate Cancer Screening—
The True Potential Remains Unknown
Laura D. Scherer, PhD; Grace Lin, MD, MAS
In 2009, routine prostate cancer screening using a prostate-
specific antigen (PSA) test was described as “the controversy
that refuses to die.”1(p1351) Unfortunately, 10 years later, the
controversy is still alive and thriving.2 Clinical trials have
failed to resolve whether or
to what degree screening
using PSA tests help reduce
prostate cancer–specific mortality, and it has long been clear
that PSA screening tests increase the diagnosis of low-risk
cancers and can lead to patient harm from potentially
unnecessary biopsies and cancer treatment. As a result,
many expert groups recommend shared decision-making
(SDM) and informed patient choice for routine prostate can-
cer screening.3,4
Patient decision aids (DAs) have been proposed as a cru-
cial tool for supporting SDM. In a new meta-analysis
reported in this issue of JAMA Internal Medicine, Riikonen
et al5 report the outcomes of DAs for prostate cancer screen-
ing relative to usual care, assessing their association with
patient knowledge, decisional conflict, screening discus-
sions, decision satisfaction, and screening decisions. The
results are disappointing; compared with usual care, these
DAs increased patient knowledge to some extent and
decreased decisional conflict but had no effect on screening
discussions, decision satisfaction, or receiving screening.
The authors conclude that “the available evidence does not
provide a compelling rationale for clinicians to use existing
decision aids to facilitate shared decision making in their
discussions with men considering undergoing prostate can-
cer screening.”
Although we agree that these data do not provide a per-
suasive case for use of the DAs included in themeta-analysis,
it would be premature to conclude on the basis of these data
that DAs do not and could not affect prostate cancer screen-
ingdecisions.One issue that this study5 highlights is that ran-
domizedclinical trialsofprostatecancerscreeningDAsvsusual
careareheterogeneous inDAcontent,design,delivery,andout-
come measures. For example, the only information that was
common to all the DAs was the purpose of prostate cancer
screening. There was considerable variation in DA presenta-
tionandmeasurementofpatientknowledge, froma1-pageflyer
received by mail, with patients’ knowledge assessed up to 3
weeks later, to an in-clinicDA intervention that included a 12-
minute video and an8-minute coaching session,with knowl-
edge assessed immediately after these interventions.5 Fur-
thermore, someDAs recommended that the patient talkwith
their doctor, while others did not, and still others actively
coached patients on how to address barriers to communica-
tion just prior to their appointment. Therewas also heteroge-
neity in communication method (eg, booklets, leaflets, com-
puter tools, video), how the DAs were implemented (eg, in
clinic, bymail), andwhenandhowtheprimaryoutcomeswere
assessed.Outcomemeasurementsalsovariedamong thestud-
ies, and the most robust outcome observed was a reduction
in decisional conflict, the only outcome forwhich therewas a
standard, validated measure. Each of these factors, if de-
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